Precautionary harm disclosure in clinical trials.
Wu
Kevin Chien-Chang
KC
National Taiwan University College of Medicine, No. 1 Ren-Ai Road, Sec. 1, Taipei100, Taiwan--Republic of China. ccwu88@ntu.edu.tw
D001569:Benzodiazepines / Q000009:adverse effects; D002986:Clinical Trials as Topic / Q000941:ethics*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects; D004345:Drug Industry / Q000941:ethics*; D026689:Ethical Analysis; D006801:Humans; D007258:Informed Consent / Q000941:ethics*; D007783:Lactones / Q000009:adverse effects; D028681:Moral Obligations; D000077152:Olanzapine; D026684:Personal Autonomy; D035842:Research Subjects; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects; D013405:Suicide; D013450:Sulfones / Q000009:adverse effects; D016896:Treatment Outcome; D014342:Truth Disclosure / Q000941:ethics*; D014481:United States; D014486:United States Food and Drug Administration
D001569:Benzodiazepines; D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D000077152:Olanzapine; D017367:Selective Serotonin Reuptake Inhibitors; D013450:Sulfones; C116926:rofecoxib